Biologics CDMO market stays fragmented as Lonza leads

The biologics contract development and manufacturing organization market remains moderately fragmented, with Lonza Group holding the largest share in 2024 and the top 10 players controlling 29% of revenue. The Business Research Company says competition is being shaped by manufacturing scale, regulatory compliance, and new standardized production frameworks aimed at faster technology transfer and more consistent output. Why it matters: - The biologics CDMO market is the manufacturing backbone for complex drugs, including monoclonal antibodies, biosimilars, and cell and gene therapies. - Competitive strength in this market can shape who wins long-term biologics development and commercialization contracts. - The market’s moderate fragmentation creates room for both global manufacturers and niche biologics specialists to gain share. What happened: - The Business Research Company published a biologics CDMO market report covering the market landscape through 2030. - Lonza Group Ltd led global sales in 2024 with a 4% market share. - Samsung Biologics Co Ltd also held a 4% share, while WuXi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Fujifilm Holdings Corporation and AGC Inc. each held 3%. - Catalent Inc., AbbVie Inc. and Grifols SA each held 2%. - The top 10 players accounted for 29% of total market revenue in 2024. The details: - The report says competitive positioning depends on advanced bioprocessing technologies, large-scale mammalian and microbial manufacturing, process optimization, fill-finish innovation and flexible manufacturing systems. - Regulatory compliance, production scalability, product quality assurance and contamination control remain central to market competition. - Lonza’s biologics division offers cell line development, mammalian and microbial manufacturing, bioconjugation, aseptic fill-finish and analytical testing services. - The company’s services support biologic drug development, manufacturing scalability, process reliability and regulatory compliance across biopharmaceutical and biotechnology applications. - Major companies in the market include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Fujifilm Holdings Corporation, AGC Inc., Catalent Inc., AbbVie Inc., Grifols SA, Novartis AG, JSR Corporation, Sandoz International GmbH, Emergent BioSolutions Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Kemwell Biopharma Pvt Ltd and Cytovance Biologics. - Major raw material suppliers include Merck KGaA, Danaher Corporation, Sartorius AG, Cytiva, Avantor Inc., Repligen Corporation, Corning Incorporated, Lonza Group Ltd., FUJIFILM Irvine Scientific, Asahi Kasei Corporation, Saint-Gobain, Thermo Fisher Scientific Inc., Wacker Chemie AG, Evonik Industries AG, JSR Corporation, 3M Company and GEA Group AG. - Major wholesalers and distributors include McKesson Corporation, Cencora Inc., Cardinal Health Inc., Owens & Minor Inc., DKSH Holding Ltd., Zuellig Pharma, Phoenix Group, Sinopharm Group Co. Ltd., Medipal Holdings Corporation, Shanghai Pharma Group Co. Ltd., Morris & Dickson Co. LLC, Bomi Group, Uniphar Group, Movianto and World Courier. - Major end users include F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, Novartis AG, Amgen Inc., Gilead Sciences Inc., Sanofi S.A., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Biogen Inc., Moderna Inc., CSL Limited, Takeda Pharmaceutical Company Limited, AbbVie Inc. and Novo Nordisk A/S. Between the lines: - The market’s concentration level suggests meaningful barriers to entry, including GMP compliance, heavy capital needs and specialized technical expertise. - The report frames capacity expansion, technology advancement and strategic collaborations as likely advantages for leading players. - Standardized manufacturing frameworks are emerging as a key competitive theme because they can improve efficiency, speed technology transfer and increase consistency across global sites. - Samsung Biologics launched the ExellenS manufacturing framework in October 2025, with standardized equipment systems, integrated operational processes and harmonized technology transfer across its biologics facilities. - The framework is designed to improve process reliability, regulatory consistency and commercial manufacturing execution for global biopharmaceutical clients. - The report also highlights advanced single-use bioprocessing, cell and gene therapy manufacturing expansion, AI-driven process optimization, strategic partnerships and high-capacity mammalian cell culture facilities as active strategies. What’s next: - The report expects demand for biologics manufacturing solutions to keep rising as interest grows in monoclonal antibodies, biosimilars, cell and gene therapies and flexible production capacity. - Companies that expand capacity and adopt standardized, technology-enabled manufacturing systems are positioned to strengthen their competitive standing through 2030. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics and updated trend analysis. - The company provides a free sample and the full report online at More information and the detailed market report . The bottom line: - Biologics CDMO competition is still spread across a broad field, but scale, compliance and standardized manufacturing are separating the leaders from the rest.